vs
Health Catalyst, Inc.（HCAT）与PUMA BIOTECHNOLOGY, INC.（PBYI）财务数据对比。点击上方公司名可切换其他公司
PUMA BIOTECHNOLOGY, INC.的季度营收约是Health Catalyst, Inc.的1.0倍（$75.5M vs $74.7M），PUMA BIOTECHNOLOGY, INC.同比增速更快（27.7% vs -6.2%），PUMA BIOTECHNOLOGY, INC.自由现金流更多（$14.4M vs $9.6M），过去两年PUMA BIOTECHNOLOGY, INC.的营收复合增速更高（31.3% vs -0.0%）
Catalyst制药公司是一家总部位于美国佛罗里达州科勒尔盖布尔斯的生物制药企业，专注于开发罕见病治疗药物。其开发的阿米夫斯汀磷酸盐商品名为Firdapse，原本已获FDA批准用于成人兰伯特-伊顿肌无力综合征（LEMS）的治疗，2018年11月又获批可用于6岁及以上儿童LEMS患者。
彪马生物技术是一家公开上市的生物制药企业，总部位于美国加利福尼亚州洛杉矶，专注于创新药物研发相关业务，在生物制药领域开展研发与商业化运营。
HCAT vs PBYI — 直观对比
营收规模更大
PBYI
是对方的1.0倍
$74.7M
营收增速更快
PBYI
高出33.9%
-6.2%
自由现金流更多
PBYI
多$4.7M
$9.6M
两年增速更快
PBYI
近两年复合增速
-0.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $74.7M | $75.5M |
| 净利润 | $-91.0M | — |
| 毛利率 | — | 69.3% |
| 营业利润率 | -115.3% | 22.7% |
| 净利率 | -121.9% | — |
| 营收同比 | -6.2% | 27.7% |
| 净利润同比 | -340.3% | — |
| 每股收益（稀释后） | $-1.29 | $0.26 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HCATPBYI
| Q4 25 | $74.7M | $75.5M | ||
| Q3 25 | $76.3M | $54.5M | ||
| Q2 25 | $80.7M | $52.4M | ||
| Q1 25 | $79.4M | $46.0M | ||
| Q4 24 | $79.6M | $59.1M | ||
| Q3 24 | $76.4M | $80.5M | ||
| Q2 24 | $75.9M | $47.1M | ||
| Q1 24 | $74.7M | $43.8M |
净利润HCATPBYI
| Q4 25 | $-91.0M | — | ||
| Q3 25 | $-22.2M | $8.8M | ||
| Q2 25 | $-41.0M | $5.9M | ||
| Q1 25 | $-23.7M | $3.0M | ||
| Q4 24 | $-20.7M | — | ||
| Q3 24 | $-14.7M | $20.3M | ||
| Q2 24 | $-13.5M | $-4.5M | ||
| Q1 24 | $-20.6M | $-4.8M |
毛利率HCATPBYI
| Q4 25 | — | 69.3% | ||
| Q3 25 | 52.6% | 77.7% | ||
| Q2 25 | — | 76.5% | ||
| Q1 25 | — | 77.1% | ||
| Q4 24 | — | 76.4% | ||
| Q3 24 | 47.5% | 63.9% | ||
| Q2 24 | — | 77.4% | ||
| Q1 24 | — | 75.5% |
营业利润率HCATPBYI
| Q4 25 | -115.3% | 22.7% | ||
| Q3 25 | -22.9% | 17.6% | ||
| Q2 25 | -46.0% | 12.7% | ||
| Q1 25 | -25.4% | 8.7% | ||
| Q4 24 | -22.0% | 22.6% | ||
| Q3 24 | -17.9% | 27.4% | ||
| Q2 24 | -20.8% | -4.6% | ||
| Q1 24 | -30.5% | -5.3% |
净利率HCATPBYI
| Q4 25 | -121.9% | — | ||
| Q3 25 | -29.1% | 16.2% | ||
| Q2 25 | -50.8% | 11.2% | ||
| Q1 25 | -29.9% | 6.5% | ||
| Q4 24 | -26.0% | — | ||
| Q3 24 | -19.3% | 25.2% | ||
| Q2 24 | -17.8% | -9.6% | ||
| Q1 24 | -27.6% | -11.0% |
每股收益（稀释后）HCATPBYI
| Q4 25 | $-1.29 | $0.26 | ||
| Q3 25 | $-0.32 | $0.17 | ||
| Q2 25 | $-0.59 | $0.12 | ||
| Q1 25 | $-0.35 | $0.06 | ||
| Q4 24 | $-0.33 | $0.40 | ||
| Q3 24 | $-0.24 | $0.41 | ||
| Q2 24 | $-0.23 | $-0.09 | ||
| Q1 24 | $-0.35 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $95.7M | $97.5M |
| 总债务越低越好 | $153.3M | $22.7M |
| 股东权益账面价值 | $245.8M | $130.3M |
| 总资产 | $502.6M | $216.3M |
| 负债/权益比越低杠杆越低 | 0.62× | 0.17× |
8季度趋势，按日历期对齐
现金及短期投资HCATPBYI
| Q4 25 | $95.7M | $97.5M | ||
| Q3 25 | $91.5M | $94.4M | ||
| Q2 25 | $97.3M | $96.0M | ||
| Q1 25 | $342.0M | $93.2M | ||
| Q4 24 | $392.0M | $101.0M | ||
| Q3 24 | $387.3M | $96.7M | ||
| Q2 24 | $308.3M | $96.8M | ||
| Q1 24 | $327.8M | $107.2M |
总债务HCATPBYI
| Q4 25 | $153.3M | $22.7M | ||
| Q3 25 | $153.1M | $34.0M | ||
| Q2 25 | $153.0M | $45.3M | ||
| Q1 25 | $382.9M | $56.7M | ||
| Q4 24 | $382.4M | $68.0M | ||
| Q3 24 | $345.0M | $79.3M | ||
| Q2 24 | — | $90.7M | ||
| Q1 24 | — | $102.0M |
股东权益HCATPBYI
| Q4 25 | $245.8M | $130.3M | ||
| Q3 25 | $331.9M | $115.3M | ||
| Q2 25 | $347.5M | $104.7M | ||
| Q1 25 | $376.8M | $97.1M | ||
| Q4 24 | $365.2M | $92.1M | ||
| Q3 24 | $355.0M | $71.1M | ||
| Q2 24 | $357.0M | $48.5M | ||
| Q1 24 | $357.2M | $51.0M |
总资产HCATPBYI
| Q4 25 | $502.6M | $216.3M | ||
| Q3 25 | $587.1M | $202.9M | ||
| Q2 25 | $616.2M | $194.9M | ||
| Q1 25 | $891.5M | $196.2M | ||
| Q4 24 | $858.9M | $213.3M | ||
| Q3 24 | $813.0M | $220.7M | ||
| Q2 24 | $691.7M | $205.0M | ||
| Q1 24 | $695.1M | $214.1M |
负债/权益比HCATPBYI
| Q4 25 | 0.62× | 0.17× | ||
| Q3 25 | 0.46× | 0.30× | ||
| Q2 25 | 0.44× | 0.43× | ||
| Q1 25 | 1.02× | 0.58× | ||
| Q4 24 | 1.05× | 0.74× | ||
| Q3 24 | 0.97× | 1.12× | ||
| Q2 24 | — | 1.87× | ||
| Q1 24 | — | 2.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $9.9M | $14.4M |
| 自由现金流经营现金流 - 资本支出 | $9.6M | $14.4M |
| 自由现金流率自由现金流/营收 | 12.9% | 19.1% |
| 资本支出强度资本支出/营收 | 0.4% | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-697.0K | $41.7M |
8季度趋势，按日历期对齐
经营现金流HCATPBYI
| Q4 25 | $9.9M | $14.4M | ||
| Q3 25 | $-464.0K | $9.7M | ||
| Q2 25 | $-9.0M | $14.1M | ||
| Q1 25 | $280.0K | $3.6M | ||
| Q4 24 | $-3.5M | $15.6M | ||
| Q3 24 | $6.2M | $11.0M | ||
| Q2 24 | $1.6M | $1.0M | ||
| Q1 24 | $10.3M | $11.2M |
自由现金流HCATPBYI
| Q4 25 | $9.6M | $14.4M | ||
| Q3 25 | $-719.0K | $9.7M | ||
| Q2 25 | $-9.2M | $14.1M | ||
| Q1 25 | $-390.0K | $3.6M | ||
| Q4 24 | $-3.9M | $15.6M | ||
| Q3 24 | $5.5M | $11.0M | ||
| Q2 24 | $1.3M | $1.0M | ||
| Q1 24 | $10.1M | — |
自由现金流率HCATPBYI
| Q4 25 | 12.9% | 19.1% | ||
| Q3 25 | -0.9% | 17.7% | ||
| Q2 25 | -11.4% | 26.8% | ||
| Q1 25 | -0.5% | 7.7% | ||
| Q4 24 | -4.9% | 26.4% | ||
| Q3 24 | 7.2% | 13.7% | ||
| Q2 24 | 1.7% | 2.1% | ||
| Q1 24 | 13.5% | — |
资本支出强度HCATPBYI
| Q4 25 | 0.4% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 0.3% | 0.0% | ||
| Q1 25 | 0.8% | 0.1% | ||
| Q4 24 | 0.5% | 0.0% | ||
| Q3 24 | 0.9% | 0.0% | ||
| Q2 24 | 0.4% | 0.0% | ||
| Q1 24 | 0.3% | 0.0% |
现金转化率HCATPBYI
| Q4 25 | — | — | ||
| Q3 25 | — | 1.10× | ||
| Q2 25 | — | 2.41× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.54× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HCAT
| Recurring Technology | $51.9M | 69% |
| Professional Services | $22.8M | 31% |
PBYI
暂无分部数据
